MedTrace Logo

Effect of a New HA Filler in Correcting Nasolabial Fold

NCT06574750 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-08-28

No results posted yet for this study

Summary

The investigators aimed to evaluate the efficacy and safety of new HA filler for nasolabial fold correction

Conditions

  • Aging Problems

Interventions

DRUG

CUREAⓇ (ARIBIO, Ltd., Seoul, Republic of Korea)

Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.

DRUG

JuvedermⓇ (Q-Med AB, Uppsala, Sweden)

Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Bo Ri Kim, M.D., Ph.D. · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-16
Primary Completion
2023-05-08
Completion
2023-05-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06574750 on ClinicalTrials.gov